Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cyprotex-an-evotec-company-expands-into-new-uk-facility-at-alderley-park-5434
Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan)
Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-an-integrated-drug-discovery-collaboration-with-asahi-kasei-pharma-japan-5432
Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics
Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP („Fibrocor“), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-establish-strategic-partnership-to-launch-fibrocor-therapeutics-5430
Haplogen´s novel antiviral target partnered with Evotec published in 'Nature'
Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/haplogens-novel-antiviral-target-partnered-with-evotec-published-in-nature-5428
Evotec and Eternygen to develop novel metabolic disease therapy
Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH („Eternygen“) by becoming an investor in addition to being a pre-clinical drug discovery partner. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-to-develop-novel-metabolic-disease-therapy-5426
Ad hoc: Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases
Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple other neurodegenerative disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-celgene-enter-into-drug-discovery-collaboration-for-neurodegenerative-diseases-5420
Evotec completes acquisition of Cyprotex PLC
Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-cyprotex-plc-5418
Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases
Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-enter-into-drug-discovery-collaboration-for-neurodegenerative-diseases-6
Evotec and Forge Therapeutics form strategic 'superbug' alliance
Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. („Forge“) to advance its novel Gram-negative antibiotic programme targeting „LpxC“ for the treatment of bacterial infections including those caused by drug resistant ’superbugs‘. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-forge-therapeutics-form-strategic-superbug-alliance-8
Evotec and Merck enter into agreements to collaborate on target discovery technologies
Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck’s portfolio of genome editing technologies with Evotec’s versatile screening platforms and disease expertise. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-merck-enter-into-agreements-to-collaborate-on-target-discovery-technologies-5414